Monitoring of metabolic adverse events of second-generation antipsychotics in a naive paediatric population followed in mental health outpatient and inpatient clinical settings: MEMAS prospective study protocol

Monitoring of metabolic adverse events of second-generation antipsychotics in a naive paediatric population followed in mental health outpatient and inpatient clinical settings: MEMAS prospective study protocol

Introduction Second-generation antipsychotics (SGAs) are widely used in the paediatric population. It is currently established that SGAs may induce metabolic adverse events (AEs) such as weight gain, perturbation of blood lipids or glucose with risk of potential cardiovascular morbidity and mortalit...

Full description

Bibliographic Details
Main Authors: Marie-Line Menard, Drigissa Ilies, Pascale Abadie, Thaïna Jean-Baptiste, Rachel Choquette, Anne-Sophie Huet, Leila Ben Amor
Format: Article
Language:English
Published: BMJ Publishing Group 2021-01-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/1/e040764.full

Internet

https://bmjopen.bmj.com/content/11/1/e040764.full

Similar Items